Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation

Department of Neuroscience, University of Tor Vergata, Via Montpellier 1, 00133 Roma, Italy.
Journal of Biological Chemistry (Impact Factor: 4.57). 01/2005; 280(1):685-94. DOI: 10.1074/jbc.M407360200
Source: PubMed

ABSTRACT The conversion of the normal cellular prion protein (PrP(C)) into the abnormal scrapie isoform (PrP(Sc)) is a key feature of prion diseases. The pathogenic mechanisms and the subcellular sites of the conversion are complex and not completely understood. In particular, little is known on the role of the early compartment of the secretory pathway in the processing of PrP(C) and in the pathogenesis of prion diseases. In order to interfere with the intracellular traffic of endogenous PrP(C) we have generated two anti-prion single chain antibody fragments (scFv) directed against different epitopes, each fragment tagged either with a secretory leader or with the ER retention signal KDEL. The stable expression of these constructs in PC12 cells allowed us to study their specific effects on the synthesis, maturation, and processing of endogenous PrP(C) and on PrP(Sc) formation. We found that ER-targeted anti-prion scFvs retain PrP(C) in the ER and inhibit its translocation to the cell surface. Retention in the ER strongly affects the maturation and glycosylation state of PrP(C), with the appearance of a new aberrant endo-H sensitive glycosylated species. Interestingly, ER-trapped PrP(C) acquires detergent insolubility and proteinase K resistance. Furthermore, we show that ER-targeted anti-prion antibodies prevent PrP(Sc) accumulation in nerve growth factor-differentiated PC12 cells, providing a new tool to study the molecular pathology of prion diseases.

Download full-text


Available from: Vito Vetrugno, Aug 14, 2015
  • Source
    • "Initially, the constant region genes (C␥, C␧ and C␣) were expressed as transfectomas to produce bovine × mouse chimeric antibodies [5]. Now recombinant scFvs of bovine origin have been developed against foot-and-mouth disease [20] and prion protein [21] [22] [23]. Earlier we constructed functional scFv [24] against bovine herpes virus type-1 (BoHV-1) expressed in secretory form in Pichia pastoris [25] [26] [27] under the influence of methanol regulated promoters . "
    [Show abstract] [Hide abstract]
    ABSTRACT: We constructed functional recombinant single chain Fv (scFv) against bovine herpes virus type 1 (BoHV-1), aetiological agent of respiratory and genital diseases in cattle for which available vaccines do not provide adequate protection. The scFv against BoHV-1 with 18 amino acid long flexible linker (scFv3-18L; monomeric form) recognized target antigen and, also, neutralized BoHV-1 in vitro. A comparison with recombinant scFv with 7 amino acid linker against BoHV-1 (scFv1-7L), capable of forming diabodies, indicated that a relatively higher concentration (two-fold) of monomer scFv3-18L is needed for virus neutralization as compared to scFv1-7L. A single point replacement mutation (Asp98 to Gly98) in the framework-3 (FR3) variable-region of scFv with 18 amino acid linker (scFv4m-18L), however, affected the viral neutralization in a dose-dependent manner where 2.7 fold higher mutant scFv concentration was required to achieve virus neutralization. Despite differences in dose-dependent viral neutralization of the mutant scFv-18L, it detected viral antigen in an immunofluorescent assay. The outlined experiments demonstrate that recombinant scFv against BoHV-1, whether expressed as scFv or diabody, provide an effective antibody based therapeutic and immunodiagnostic protein. Further, single point substitution mutation in the FR3 can affect viral neutralization dynamics without affecting qualitative viral antigen recognition.
    Vaccine 08/2011; 29(45):7905-12. DOI:10.1016/j.vaccine.2011.08.077 · 3.49 Impact Factor
  • Source
    • "HIV Tat protein [Bai et al., 2003] or HBV surface and core antigens [Serruys et al., 2009, 2010]); transplantation; protein mutationassociated diseases (e.g. prion proteins [Cardinale et al., 2005]); and, protein aggregation diseases (Alzheimer's [Lynch et al., 2008]). To circumvent present intrabody therapy issues related to in vivo gene delivery, the intrabody in vitro validated anti-HBe V NAR , could be engineered as a humanized antibody for in vivo immunoglobulin therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Hepatitis B virus precore protein is processed in the endoplasmic reticulum (ER) into secreted hepatitis B e antigen (HBeAg), which acts as an immune tolerogen to establish chronic infection. Downregulation of secreted HBeAg should improve clinical outcome, as patients who effectively respond to current treatments (IFN-α) have significantly lower serum HBeAg levels. Here, we describe a novel reagent, a single variable domain (V(NAR)) of the shark immunoglobulin new antigen receptor (IgNAR) antibodies. V(NAR)s possess advantages in stability, size (~14 kDa) and cryptic epitope recognition compared to conventional antibodies. The V(NAR) domain displayed biologically useful affinity for recombinant and native HBeAg, and recognised a unique conformational epitope. To assess therapeutic potential in targeting intracellular precore protein to reduce secreted HBeAg, the V(NAR) was engineered for ER-targeted in vitro delivery to function as an intracellular antibody (intrabody). In vitro data from HBV/precore hepatocyte cell lines demonstrated effective intrabody regulation of precore/HBeAg.
    Virology 03/2011; 411(1):132-41. DOI:10.1016/j.virol.2010.12.034 · 3.28 Impact Factor
  • Source
    • "Anti-PrP antibodies are able to cure prion-infected cells (Beringue et al., 2004; Cardinale et al., 2005; Enari et al., 2001; Feraudet et al., 2005; Kim et al., 2004; Peretz et al., 2001; Perrier et al., 2004). In vivo, using peripheral TSE infection animal models, continuous intraperitoneal (i.p.) treatment with anti-PrP antibodies delays disease development, with variable efficacy (Sigurdsson et al., 2003; White et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prion diseases are transmissible neurodegenerative disorders for which no therapeutic or prophylactic regimens exist. Passive immunization with appropriate antibodies directed against the cellular form of the prion protein (PrPC) can delay the onset of prion disease after peripheral infection, but mechanisms and parameters determining their in vivo efficacy remain unknown. In the present study, we characterized the main pharmacokinetic properties of anti-PrP antibodies in different mouse models expressing various levels of PrPC (Prnp(0/0), C57BL/6 and tga20 mice) in correlation with therapeutic effect. Plasma levels of free antibodies, total endogenous PrPC and PrPC-antibody complexes were monitored after a single intraperitoneal monoclonal antibody (mAb) injection. Efficacy in delaying PrPSc peripheral accumulation seemed to be associated with mAb capacity to form long-lasting complexes with endogenous PrPC in the plasma. In agreement with previous observations on cellular models of transmissible spongiform encephalopathy infection, we observed that injection of anti-PrP antibodies induced a large (up to 100-fold) increase in circulating PrPC. Finally, the most efficient antibody extended the lifespan of infected animals greatly. These results allowed us to define critical characteristics of anti-PrP mAbs associated with therapeutic efficacy and could constitute a useful reference for designing optimized passive immunotherapies for prion diseases.
    Journal of General Virology 06/2010; 91(Pt 6):1635-45. DOI:10.1099/vir.0.018077-0 · 3.53 Impact Factor
Show more